ARTICLE | Company News
University of New Mexico, SolaranRx deal
September 29, 2014 7:00 AM UTC
SolaranRx received an exclusive option from the university to license exclusive, worldwide rights to preclinical radiolabeled peptides against the melanocortin 1 receptor (MC1R) to treat metastatic m...